Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma

To investigate the safety of delivering arsenic trioxide (ATO) in combination with stereotactic radiotherapy in recurrent malignant glioma by performing an open label, Phase I dose escalation trial. Results from this study will provide a basis for further study of ATO combined with radiation therapy as a radiosensitizer for malignant brain tumors in future Phase II studies.

Principal Investigator

  • Iris C. Gibbs, MD, FACR

Stanford Investigator(s)

  • Paul Graham Fisher, MD
  • Susan Pillsbury
  • Griffith Harsh, MD
  • Lawrence Recht, MD
  • Huy M. Do, MD


Primary Contact:
Laurie Tupper
(650) 498-4143